Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

LUCAR-DKS1

Cell therapy (NK cells) · developed by Nanjing Legend Biotech

Early Phase 1 Most advanced trial
LEGN Developer
1 Registered trials

What is LUCAR-DKS1?

LUCAR-DKS1 is a natural killer (NK) cell therapy given by infusion after a conditioning regimen of cyclophosphamide and fludarabine. It is being studied in relapsed or refractory autoimmune diseases.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Cell therapy (NK cells)
Therapy area
Immunology
Developer
Nanjing Legend Biotech Co. (LEGN)
FDA status
Investigational, not approved in the US. Most advanced trial: Early Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07095075 Early Phase 1 Relapsed/Refractory Autoimmune Diseases Recruiting LEGN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Relapsed/Refractory Autoimmune Diseases

More from Nanjing Legend Biotech

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the LEGN page.

Follow LEGN, the company behind LUCAR-DKS1

See LEGN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

LEGN catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.